|
LHX9 |
LIM homeobox 9 |
- Regulation of expression of SLITs and ROBOs
|
|
|
|
LITAF |
lipopolysaccharide induced TNF factor |
|
|
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
|
|
LMO2 |
LIM domain only 2 |
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
|
|
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
|
|
MAP2K1 |
mitogen-activated protein kinase kinase 1 |
- MAPK3 (ERK1) activation
- Frs2-mediated activation
- Signal transduction by L1
- Uptake and function of anthrax toxins
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by MAP2K mutants
- Signaling by RAF1 mutants
|
- K-252a
- 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
- Cobimetinib
- Bosutinib
- (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
- 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
- Mirdametinib
- N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
- 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
- Trametinib
- Selumetinib
- Pimasertib
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
MAPK1 |
mitogen-activated protein kinase 1 |
- phospho-PLA2 pathway
- RAF-independent MAPK1/3 activation
- MAPK1 (ERK2) activation
- Signaling by NODAL
- Spry regulation of FGF signaling
- Signaling by Activin
- Golgi Cisternae Pericentriolar Stack Reorganization
- Frs2-mediated activation
- ERK/MAPK targets
- ERK/MAPK targets
- ERKs are inactivated
- Regulation of actin dynamics for phagocytic cup formation
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Oncogene Induced Senescence
- FCERI mediated MAPK activation
- Regulation of HSF1-mediated heat shock response
- NCAM signaling for neurite out-growth
- Recycling pathway of L1
- RSK activation
- Signal transduction by L1
- Activation of the AP-1 family of transcription factors
- Thrombin signalling through proteinase activated receptors (PARs)
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate NADPH Oxidases
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Neutrophil degranulation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signal attenuation
- Interferon gamma signaling
- Advanced glycosylation endproduct receptor signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- ESR-mediated signaling
- RUNX2 regulates osteoblast differentiation
- Regulation of PTEN gene transcription
- Regulation of the apoptosome activity
- Estrogen-stimulated signaling through PRKCZ
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Suppression of apoptosis
- Signaling downstream of RAS mutants
- Signaling by MAP2K mutants
- Signaling by MAPK mutants
- Signaling by RAF1 mutants
- FCGR3A-mediated phagocytosis
- Nuclear events stimulated by ALK signaling in cancer
- IFNG signaling activates MAPKs
- Negative Regulation of CDH1 Gene Transcription
- NPAS4 regulates expression of target genes
- NPAS4 regulates expression of target genes
- Growth hormone receptor signaling
- Signaling by LTK in cancer
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
- Acetylsalicylic acid
- Minocycline
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Colforsin
- Purvalanol
- SB220025
- Seliciclib
- Perifosine
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- Hypothemycin
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
- Turpentine
- Ulixertinib
|
|
|
MAPK3 |
mitogen-activated protein kinase 3 |
- MAPK3 (ERK1) activation
- RAF-independent MAPK1/3 activation
- ISG15 antiviral mechanism
- Signaling by NODAL
- Spry regulation of FGF signaling
- Signaling by Activin
- Frs2-mediated activation
- ERK/MAPK targets
- ERK/MAPK targets
- ERKs are inactivated
- Regulation of actin dynamics for phagocytic cup formation
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Oncogene Induced Senescence
- FCERI mediated MAPK activation
- Regulation of HSF1-mediated heat shock response
- NCAM signaling for neurite out-growth
- RSK activation
- Signal transduction by L1
- Activation of the AP-1 family of transcription factors
- Thrombin signalling through proteinase activated receptors (PARs)
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate NADPH Oxidases
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RNA Polymerase I Promoter Opening
- Signal attenuation
- Interferon gamma signaling
- Advanced glycosylation endproduct receptor signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- ESR-mediated signaling
- RUNX2 regulates osteoblast differentiation
- Regulation of PTEN gene transcription
- Regulation of the apoptosome activity
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Suppression of apoptosis
- Signaling downstream of RAS mutants
- Signaling by MAP2K mutants
- Signaling by RAF1 mutants
- FCGR3A-mediated phagocytosis
- Nuclear events stimulated by ALK signaling in cancer
- IFNG signaling activates MAPKs
- Negative Regulation of CDH1 Gene Transcription
- NPAS4 regulates expression of target genes
- NPAS4 regulates expression of target genes
- Growth hormone receptor signaling
- Signaling by LTK in cancer
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
- Sulindac
- Acetylsalicylic acid
- Minocycline
- Arsenic trioxide
- Colforsin
- Purvalanol
- 5-iodotubercidin
- Seliciclib
- Cholecystokinin
- Ulixertinib
|
|
|
MAPK8 |
mitogen-activated protein kinase 8 |
- Activation of BIM and translocation to mitochondria
- Activation of BMF and translocation to mitochondria
- NRAGE signals death through JNK
- NRAGE signals death through JNK
- NRIF signals cell death from the nucleus
- Oxidative Stress Induced Senescence
- FCERI mediated MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Activation of the AP-1 family of transcription factors
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Interleukin-38 signaling
- WNT5:FZD7-mediated leishmania damping
- Signaling by ALK fusions and activated point mutants
|
- Tamoxifen
- Minocycline
- Pyrazolanthrone
- 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE
- 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE
- N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE
- 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE
- 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide
- Halicin
|
|
|
MAPK9 |
mitogen-activated protein kinase 9 |
- Oxidative Stress Induced Senescence
- FCERI mediated MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Activation of the AP-1 family of transcription factors
- Signaling by ALK fusions and activated point mutants
|
- Minocycline
- N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide
- Fostamatinib
- Halicin
|
|
|
MECOM |
MDS1 and EVI1 complex locus |
- PKMTs methylate histone lysines
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Formation of the nephric duct
|
|
- Chronic myeloid leukemia (CML)
|
|
MED15 |
mediator complex subunit 15 |
- PPARA activates gene expression
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- RSV-host interactions
|
|
|
|
MED6 |
mediator complex subunit 6 |
- PPARA activates gene expression
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- RSV-host interactions
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
|
|
|
|
MEF2A |
myocyte enhancer factor 2A |
- ERK/MAPK targets
- Myogenesis
|
|
|
|
MEF2C |
myocyte enhancer factor 2C |
- ERK/MAPK targets
- Transcriptional activation of mitochondrial biogenesis
- Myogenesis
- MECP2 regulates transcription factors
- Heme signaling
- Cardiogenesis
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
|
|
- Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
|
|
MYC |
MYC proto-oncogene, bHLH transcription factor |
- Transcription of E2F targets under negative control by DREAM complex
- Signaling by ALK
- NOTCH1 Intracellular Domain Regulates Transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- MAPK6/MAPK4 signaling
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- RUNX3 regulates WNT signaling
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
- Regulation of CDH1 mRNA translation by microRNAs
- Regulation of NFE2L2 gene expression
- Regulation of PD-L1(CD274) transcription
|
- Acetylsalicylic acid
- Dimethyl sulfoxide
- Doconexent
- Nadroparin
|
- Penile cancer
- Breast cancer
- Laryngeal cancer
- Oral cancer
- Multiple myeloma
- Kaposi's sarcoma
- Ovarian cancer
- Choriocarcinoma
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Burkitt lymphoma
- Small cell lung cancer
- Osteosarcoma
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
|
|
MYOCD |
myocardin |
|
|
|
|
NAGK |
N-acetylglucosamine kinase |
- Synthesis of UDP-N-acetyl-glucosamine
|
|
|
|
NCOA6 |
nuclear receptor coactivator 6 |
- BMAL1:CLOCK,NPAS2 activates circadian expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Regulation of lipid metabolism by PPARalpha
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Cytoprotection by HMOX1
- Heme signaling
- Formation of WDR5-containing histone-modifying complexes
- Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
|
|
|
NEDD4L |
NEDD4 like E3 ubiquitin protein ligase |
- Budding and maturation of HIV virion
- Downregulation of TGF-beta receptor signaling
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Stimuli-sensing channels
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
NEDD9 |
neural precursor cell expressed, developmentally down-regulated 9 |
|
|
|
|
NEFM |
neurofilament medium chain |
|
|
|